![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 19, 2025
Patient-reported outcomes research has led to many discoveries that have influenced current research priorities and the way the Group designs its trials
December 23, 2024
Julie Brahmer, Naomi Haas, and Jedd Wolchok offer insights into a complicated issue that pertains to biomarker testing for treatment selection
November 25, 2024
Several themes emerged as key areas of focus for ECOG-ACRIN during the Fall 2024 Group Meeting
November 25, 2024
In an annual evaluation, 54 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
October 17, 2024
The Patient-Reported Outcomes (PRO) Advisory Group guides study investigators on how best to include PRO measures and endpoints in clinical trials
October 17, 2024
The Journal of Clinical Oncology has published a proposal to jump-start correlative research, which is almost at a standstill
May 1, 2024
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
February 9, 2024
Colleagues at ThedaCare and the Metro-Minnesota Community Oncology Research Consortium share their perspectives on facilitating just-in-time access to NCTN therapeutic trials
December 19, 2023
The Fall 2023 Group Meeting was notable for a prominent increase in attention to diversity, equity, and inclusion
December 19, 2023
Elevating the role of APPs as partners in the clinic will help to reinforce the important role clinical trials play in cancer care and strengthen accrual efforts
December 19, 2023
In an annual evaluation, 46 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
October 19, 2023
Following the recent Nature Medicine publication of lessons from the NCI-MATCH trial, two new podcasts discuss the pitfalls and promises of precision oncology—and opportunities to guide the field as it moves forward